Stock Events

Stock Events

Enlivex 

$1.1000
36
-$0.06-5.17% Friday 20:00
+$0.00+0%Friday 23:00After hours

Statistics

Day High
1.105
Day Low
1.1
52W High
27.15
52W Low
1.02
Volume
2,318
Avg. Volume
-
Mkt Cap
19.23M
P/E Ratio
0.02
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7DecExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.31
-0.24
-0.18
-0.11
Expected EPS
-0.28
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
1.24BNet Income

Analyst Ratings

80.00Average Price Target
The highest estimate is 80.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENLV. It's not an investment recommendation.
Amazon
8
AMZN
Apple
7
AAPL
Tesla
7
TSLA
NVIDIA
6
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.26B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.

About

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Show more...
CEO
Oren Hershkovitz
Employees
34
Country
Israel
ISIN
IL0011319527
WKN
000A119KH

Listings

STU
DE
1BT.STU
F
DE
1BT.F
XNAS
US
ENLV
BOATS
BOATS
ENLV.BOATS

0 Comments

Share your thoughts

FAQ

What is Enlivex stock price today?▼
The current price of ENLV is $1.10 USD — it has decreased by -5.17% in the past 24 hours. Watch Enlivex stock price performance more closely on the chart.
What is Enlivex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Enlivex stocks are traded under the ticker ENLV.
Is Enlivex stock price growing?▼
ENLV stock has fallen by -18.52% compared to the previous week, the month change is a -49.54% fall, over the last year Enlivex has showed a -99.54% decrease.
What is Enlivex market cap?▼
Today Enlivex has the market capitalization of 19.23M
When is the next Enlivex earnings date?▼
Enlivex is going to release the next earnings report on December 07, 2026.
What were Enlivex earnings last quarter?▼
ENLV earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.31 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enlivex revenue for the last year?▼
Enlivex revenue for the last year amounts to 0 USD.
What is Enlivex net income for the last year?▼
ENLV net income for the last year is 1.24B USD.
How many employees does Enlivex have?▼
As of September 05, 2026, the company has 34 employees.
In which sector is Enlivex located?▼
Enlivex operates in the Health & Wellness sector.
When did Enlivex complete a stock split?▼
The last stock split for Enlivex was on July 09, 2026 with a ratio of 1:15.
Where is Enlivex headquartered?▼
Enlivex is headquartered in Ness Ziona, Israel.